Seminars in Nuclear Medicine
Volume 37, Issue 4 , Pages 286-302 , July 2007

Neuroblastoma and Other Neuroendocrine Tumors

  • Robert Howman-Giles, MB, BS, MD, FRACP, DDU

      Affiliations

    • Department of Nuclear Medicine, Children’s Hospital at Westmead, Sydney, NSW, Australia.
    • Discipline of Pediatrics and Child Health, University of Sydney, Sydney, NSW, Australia.
    • Corresponding Author InformationAddress reprint requests to Robert Howman-Giles, MB, BS, MD, FRACP, DDU, Department of Nuclear Medicine, Children’s Hospital at Westmead, Locked Bag 4001, Westmead, Sydney, NSW 2145, Australia.
    • ,
  • Peter J. Shaw, MA, MB, BS, MRCP, FRACP

      Affiliations

    • Discipline of Pediatrics and Child Health, University of Sydney, Sydney, NSW, Australia.
    • Department of Oncology, Children’s Hospital at Westmead, Sydney, NSW, Australia.
    • ,
  • Roger F. Uren, MB, BS, MD, FRACP, DDU

      Affiliations

    • Department of Nuclear Medicine, Children’s Hospital at Westmead, Sydney, NSW, Australia.
    • Department of Medicine, University of Sydney, Sydney, NSW, Australia.
    • ,
  • David K.V. Chung, MB, BS, DCH, FRACP, DDU

      Affiliations

    • Department of Nuclear Medicine, Children’s Hospital at Westmead, Sydney, NSW, Australia.

References 

  1. Brodeur GM, Maris JM. Neuroblastoma. In:  Pizzo PA,  Poplack DG editor. Principles and Practice of Pediatric Oncology. Philadelphia, PA: Lippincott Williams and Wilkins; 2001;p. 895–937
  2. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol. 1999;17:2264–2279
  3. Evans A, D’Angio G. Age at diagnosis and prognosis in children with neuroblastoma. J Clin Oncol. 2005;27:6443–6444
  4. London WR, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group. J Clin Oncol. 2005;23:6459–6465
  5. Evans A, D’Angio G. Age at diagnosis and prognosis in children with neuroblastoma. J Clin Oncol. 2005;27:6443–6444
  6. George R, London W, Cohn S, et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: A pediatric oncology group study. J Clin Oncol. 2005;23:6466–6473
  7. Lonergan GJ, Schwab CM, Suarez ES, et al. Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: Radiologic-pathologic correlation. Radiographics. 2002;22:911–934
  8. Weinstein J, Katzenstein H, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. The Oncologist. 2003;8:278–292
  9. Evans AE, D’Angio GJ, Propert K, et al. Prognostic factors in neuroblastoma. Cancer. 1987;59:1853–1859
  10. Mitchell W, Davalos-Gonzalez Y, Brumm VL, et al. Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae. Pediatrics. 2002;109:86–89
  11. Mitchell WG, Snodgrass SR. Opsoclonus-ataxia due to childhood neural crest tumors: A chronic neurologic problem. J Child Neurol. 1990;5:153–158
  12. Parisi MT, Hattner RS, Matthay KK, et al. Optimized diagnostic strategy for neuroblastoma in opsoclonus-myoclonus. J Nucl Med. 1993;34:1922–1926
  13. Davies RP, Slavotinek JP, Dorney SFA. VIP secreting tumors in infancy: A review of radiological appearances. Pediatr Radiol. 1990;20:504–508
  14. Brodeur G, Pritchard J, Berthold F, et al. Revisions of the International Criteria for Neuroblastoma Diagnosis, Staging, and Response to Treatment. J Clin Oncol. 1993;11:1466–1477
  15. Brodeur GM. Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer. 2003;3:203–216
  16. Look AT, Hayes FA, Nitschke R, et al. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med. 1984;311:231–235
  17. Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224:1121–1124
  18. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985;313:1111–1116
  19. Tonini GP, Boni L, Pession A, et al. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: The Italian experience in 295 children. J Clin Oncol. 1997;15:85–93
  20. Schmidt ML, Lal A, Seeger RC, et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: A children’s cancer group study. J Clin Oncol. 2005;23:6474–6480
  21. Schmidt ML, Lukens JN, Seeger RC, et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective children’s cancer group study. J Clin Oncol. 2000;18:1260–1268
  22. Brown N. Neuroblastoma tumour genetics: Clinical and biological aspects. J Clin Pathol. 2001;54:897–910
  23. Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999;86:364–372
  24. Shoko G, Shunsuke U, Gerbing RB, et al. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors (A report from the Children’s Cancer Group). Cancer. 2001;92:2699–2708
  25. Breslow N, McCann B. Statistical estimation of the prognosis for children with neuroblastoma. Cancer Res. 1971;31:2098–2103
  26. Kushner BH, Cheung N-KV, LaQuaglia MP, et al. Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol. 1996;14:373–381
  27. Bagatell R, Rumcheva P, London WB, et al. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. J Clin Oncol. 2005;23:8819–8827
  28. Nickerson HJ, Matthay KK, Seeger RC, et al. Favorable biology and outcome of stage IVS neuroblastoma with supportive care or minimal therapy: A children’s cancer group study. J Clin Oncol. 2000;18:477–486
  29. Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcomes of stages 1 and 2 neuroblastoma treated with surgery as primary therapy: A children’s cancer group study. J Clin Oncol. 2000;18:18–26
  30. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis retinoic acid. N Engl J Med. 1999;341:1165–1173
  31. Kushner BH. Neuroblastoma: A disease requiring a multitude of imaging studies. J Nucl Med. 2004;45:1172–1188
  32. Pearson ADJ, Craft AW, Pinkerton CR, et al. High-dose rapid schedule chemotherapy for disseminated neuroblastoma. Eur J Cancer. 1992;28A:1654–1659
  33. Kushner BH, LaQuaglia MP, Bonilla MA, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over one year of age. J Clin Oncol. 1994;12:2607–2613
  34. Hartmann O, Valteau-Couanet D, Vassal G, et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: Multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant. 1999;23:789–795
  35. Kushner BH, Wolden S, LaQuaglia MP, et al. Hyperfractionated low-dose (21Gy) radiotherapy for high-risk neuroblastoma following intensive chemotherapy and surgery. J Clin Oncol. 2001;19:2821–2828
  36. Pashanker FD, O’Dorisio MS, Menda Y. MIBG and somatostatin receptor analogs in children: Current concepts on diagnostic and therapeutic use. J Nucl Med. 2005;46:55S–61S
  37. Golding SJ, McElwain TJ, Husband JE. The role of computed tomography in the management of children with advanced neuroblastoma. Br J Radiol. 1984;57:661–666
  38. Siegel MJ, Ishwaran H, Fletcher BD, et al. Staging of neuroblastoma at imaging: Report of the Radiology Diagnostic Oncology Group. Radiology. 2002;223:168–175
  39. Lowe RE, Cohen MD. Computed tomographic evaluation of Wilms tumor and neuroblastoma. RadioGraphics. 1984;4:915–928
  40. Rosenfield NS, Leonidas JC, Barwick KW. Aggressive neuroblastoma simulating Wilms’ tumor. Radiology. 1988;166:165–167
  41. Ng YY, Kingston JE. The role of radiology in the staging of neuroblastoma. Clin Radiol. 1993;47:226–235
  42. Pfluger T, Schmied C, Porn U, et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. AJR Am J Roentgenol. 2002;181:1115–1124
  43. Fletcher BD, Kopiwoda SY, Strandjord SE, et al. Abdominal neuroblastoma: Magnetic resonance imaging and tissue characterization. Radiology. 1985;155:699
  44. Sofka CM, Semelka RC, Kelekis NL, et al. Magnetic resonance imaging of neuroblastoma using current techniques. Magn Reson Imaging. 1999;17:193–198
  45. Tanabe M, Takahashi H, Ohnuma N, et al. Evaluation of bone marrow metastases of neuroblastoma and changes after chemotherapy by MRI. Med Pediatr Oncol. 1993;21:54–59
  46. Tanabe M, Ohnuma N, Iwai J, et al. Bone marrow metastases of neuroblastoma analysed by MRI and its influence on prognosis. Med Pediatr Oncol. 1995;24:292–299
  47. Lebtahi N, Gudinchet F, Nenadov-Beck M, Delaloye AB, et al. Evaluating bone marrow metastasis of neuroblastoma with iodine-123-MIBG scintigraphy and MRI. J Nucl Med. 1997;38:1389–1392
  48. Howman-Giles RB, Gilday DL, Ash JM. Radionuclide skeletal survey in neuroblastoma. Radiology. 1979;131:497–502
  49. Heisel MA, Miller JH, Reid BS, et al. Radionuclide bone scan in neuroblastoma. Pediatrics. 1983;71:206–209
  50. Smith FW, Gilday DL, Ash JM, et al. Primary neuroblastoma uptake of 99mtechnetium methylene diphosphonate. Radiology. 1980;137:501–504
  51. Heyman S, Evans AE, D’Angio GJ. I-131 metaiodobenzylguanidine: Diagnostic use in neuroblastoma patients in relapse. Med Pediatr Oncol. 1988;16:337–340
  52. Yeh SDJ, Helson L, Benhua RS. Correlation between iodine-131 MIBG imaging and biological markers in advanced neuroblastoma. Clin Nucl Med. 1988;13:46–52
  53. Jacobs A, Delree M, Desprechins B, et al. Consolidating the role of *I-MIBG-scintigraphy in childhood neuroblastoma: Five years of clinical experience. Pediatr Radiol. 1990;20:157–159
  54. Gordon I, Peters AM, Gutman A, et al. Skeletal assessment in neuroblastoma-the pitfalls of iodine-123-MIBG scans. J Nucl Med. 1990;31:129–134
  55. Shulkin BL, Shapiro B, Hutchinson RJ. Iodine-131-metaiodobenzylguanidine and bone scintigraphy for the detection of neuroblastoma. J Nucl Med. 1992;33:1735–1740
  56. Wieland DM, Swanson DP, Brown LE, et al. Imaging the adrenal medulla with an I-131 labelled antiadrenergic agent. J Nucl Med. 1979;20:155–158
  57. Smets LA, Janssen M, Metwally EA, et al. Extragranular storage of the neuron blocking agent meta-iodobenzylguanidine (MIBG) in human neuroblastoma cells. Biochem Pharmacol. 1990;39:1959–1964
  58. Smets LA, Loesberg C, Janssen M, et al. Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells. Cancer Res. 1989;49:2941–2944
  59. Pashanker FD, O’Dorisio MS, Menda Y. MIBG and Somatostatin receptor analogs in children: Current concepts on diagnsotic and therapeutic use. J Nucl Med. 2005;46:55S–61S
  60. Shapiro B, Gross MD. Radiochemistry, biochemistry, and kinetics of 131I-metaiodobenzylguanidine (MIBG) and of 123I-MIBG: Clinical implications of the use of 123I-MIBG. Med Pediatr Oncol. 1987;15:170–177
  61. Montaldo PG, Lanciotti M, Casalaro A, et al. Accumulation of m-iodobenzylguanidine by neuroblastoma cells results from independent uptake and storage mechanisms. Cancer Res. 1991;51:4342–4346
  62. Sisson JC, Frager MS, Valk TW, et al. Scintigraphic localisation of phaeochromocytoma. N Engl J Med. 1981;305:12–17
  63. Geatti O, Shapiro B, Sisson JC, et al. Iodine-131 metaiodobenzylguanidine scintigraphy for the localisation of neuroblastoma: Preliminary experience in ten cases. J Nucl Med. 1985;26:736–742
  64. Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med. 1998;39:679–688
  65. Okuyama C, Sakane N, Yoshida T, et al. 123I or 125I-metaiodobenzylguanidine visualization of brown adipose tissue. J Nucl Med. 2002;9:1234–1240
  66. Corbett R, Olliff J, Fairley N, et al. A prospective comparison between magnetic resonance imaging, metaiodobenzylguanidine scintigraphy and marrow histology/cytology in neuroblastoma. Eur J Cancer. 1991;27:1560–1564
  67. Parisi MT, Greene MK, Dykes TM, et al. Efficacy of metaiodobenzylguanidine as a scintigraphic agent for the detection of neuroblastoma. Invest Radiol. 1992;27:768–773
  68. Osmanagaoglu K, lippens M, benoit Y, et al. A comparison of iodine-123 meta-iodobenzylguanidine scintigraphy and single bone marrow aspiration biopsy in the diagnosis and follow up of 26 children with neuroblastoma. Eur J Nucl Med. 1993;20:1154–1160
  69. Andrich MP, Shalaby-Rana E, Movassaghi N, et al. The role of 131-iodine-metaiodobenzylguanidine scanning in the correlative imaging of patients with neuroblastoma. Pediatrics. 1996;97:246–250
  70. Lastoria S, Maurea S, Caraco C, et al. Iodine-131 metaiodobenzylguanidine scintigraphy for localization of lesions in children with neuroblastoma: Comparison with computed tomography and ultrasonography. Eur J Nucl Med. 1993;20:1161–1167
  71. Paltiel HJ, Gelfand MJ, Elgazzar AH, et al. Neural crest tumors:I-123 MIBG imaging in children. Radiology. 1994;190:117–1221
  72. Bonnin F, Lumbroso J, Tenenbaum F, et al. Refining interpretation of MIBG scans in children. J Nucl Med. 1994;35:803–810
  73. Matthay KK, Berisse H, Couanet D, et al. Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients. Cancer. 2003;98:155–165
  74. Shulkin BL, Mitchell DS, Ungar DR, et al. Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies. Radiology. 1995;194:495–500
  75. Shulkin BL, Hutchingson RJ, Castle VP, et al. Neuroblastoma:positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology. 1996;199:7443–7750
  76. Kushner BH, Yeung HWD, Larson SM, et al. Extending PET scan utility to high-risk neuroblastoma: 18F-Fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up patients. J Clin Oncol. 2001;19:3397–3405
  77. Brans B, Laureys G, Schelfhout V, et al. Activity of iodine-123 metaiodobenzylguanidine in childhood neuroblastoma:lack of relation to tumour differentiation in vivo. Eur J Nucl Med. 1998;25:144–149
  78. Khafagi FA, Shapiro B, Fig LM, et al. Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med. 1989;30:481–489
  79. Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: Role on the management of neural crest tumors. Eur J Nucl med. 1994;21:561–581
  80. Perel Y, Conway J, Kletzel M, et al. Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol Oncol. 1999;21:13–18
  81. Suc A, Lumbroso J, Rubie H, et al. Metastatic neuroblastoma in children older than one year: Prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system. Cancer. 1996;77:805–811
  82. Ady N, Zucker J-M, Asselain B, et al. A new 123I-MIBG whole body scan scoring method- application to the prediction of the response to metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer. 1995;31A:256–261
  83. Matthay KK, Edeline V, Lumbroso J, et al. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event -free survival in stage IV neuroblastoma. J Clin Oncol. 2003;21:2486–2491
  84. Katzenstein HM, Cohn SL, Shore RM, et al. Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma. J Clin Oncol. 2004;22:3909–3915
  85. Frappaz D, Bonneu A, Chavot P, et al. Metaiodobenzylguanidine assessment of metastatic neuroblastoma: Observer dependency and chemosensitivity evaluation. Med Pediatr Oncol. 2000;34:237–241
  86. Kushner BH, Yeh SDJ, Kramer K, et al. Impact of MIBG scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol. 2003;21:1082–1086
  87. Leung A, Shapiro B, Hattner R, et al. Specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med. 1997;38:1352–1357
  88. Maggi M, Baldi E, Finetti G, et al. Identification, characterization and biological activity of somatostatin receptors in human neuroblastoma cell lines. Cancer Res. 1994;54:124–133
  89. Briganti V, Sestini R, Orlando C, et al. Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors. Clin Cancer Res. 1997;3:2385–2391
  90. Shalaby-Rana E, Majd M, Andrich MPL. In-111 pentetreotide scintigraphy in patients with neuroblastoma: comparison with I-131 MIBG, N-myc oncogene amplification, and patient outcome. Clin Nucl Med. 1997;22:315–319
  91. Schilling FH, Bihl H, Jacobsson H, et al. Combined111In-pentetreotide scintigraphy and 123I-mIBG scintigraphy in neuroblastoma provides prognostic information. Med Pediatr Oncol. 2000;35:688–691
  92. Goldman A, Vivian G, Gordon I, et al. Immunolocalisation of neuroblastoma using radiolabelled monoclonal antibody UJ13A. J Pediatr. 1984;105:252–256
  93. Yeh SDJ, Burch L, LaQuaglia MP, et al. Radioimmunodetection of neuroblastoma with iodine-131-3F8:correlation with biopsy, iodone-131-metaiodobenzylguanidine and standard diagnostic modalities. J Nucl Med. 1991;32:769–776
  94. Berthold F, Waters W, Sieverts H, et al. Immunoscintigraphic imaging of mIBG-negative metastases in neuroblastoma. Am J Pediatr hematol Oncol. 1990;12:61–62
  95. Reuland P, Geiger L, Thelen MH, et al. Follow-up in neuroblastoma:comparison of metaiodobenzylguanidine and a chimeric anti-GD2 antibody for detection of tumor relapse and therapy response. J Pediatr Hematol Oncol. 2001;23:437–442
  96. Rigo P, Paulus P, Kaschten BJ, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med. 1996;23:1641–1674
  97. Shulkin BL. Neuroblastoma. In:  Charron M editors. Practical Pediatric PET Imaging. New York: Springer; 2006;p. 243–255
  98. Shulkin BL, Wieland DM, Baro ME, et al. PET hydroxyephedrine imaging of neuroblastoma. J Nucl Med. 1996;37:16–21
  99. Franzius C, Hermann K, Weckesser M, et al. Whole-body PET/CT with 11C-meta-hydroxyephedrine in tumors of the sympathetic nervous system: Feasibility study and comparison with 123I-MIBG SPECT/CT. J Nucl Med. 2006;47:1635–1642
  100. Mamede M, Carrasquillo JA, Chen CC, et al. Discordant localisation of 2-[F-18]-fluoro-2-deoxy-D-glucose in 6-[F-18]-fluorodopamine and [I-123]-metaiodobenzylguanidine-negative metastatic pheochromocytoma. Nucl Med Commun. 2006;27:31–36
  101. Hoefnagel CA, Lewington VJ. MIBG therapy. In:  Ell PJ,  Gambhir SS editor. Nuclear Medicine in Clinical Diagnosis and Treatment. London: Churchill Livingstone; 2004;p. 445–457
  102. Hoefnagel CA. Nuclear medicine therapy in neuroblastoma. Q J Nucl Med. 1999;43:336–343
  103. Hoefnagel CA, Voute PA, de Kraker J, et al. Radionuclide diagnosis and therapy of neural crest tumours using iodine-131 metaiodobenzylguanidine. J Nucl Med. 1987;28:308–314
  104. Matthay KK, Huberty JP, Hattner RS, et al. Efficacy and safety of [131I] metaiodobenzylguanidine therapy for patients with refractory neuroblastoma. J Nucl Boil Med. 1991;35:244–247
  105. Tepmongkol S. Heyman S: 131I MIBG Therapy in neuroblastoma: Mechanisms, rationale, and current status. Med Pediatr Oncol. 1999;32:427–431
  106. Hoefnagel CA. Radionuclide therapy in children with neuroblastoma. Proc Ann Cong Eur Assoc Nucl Med. 2003;84–85
  107. Schmidt M, Simon T, Hero B, et al. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? (A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications of The German Neuroblastoma Trial NB2004). Nuklearmedizin. 2006;45:145–151
  108. Howard JP, Maris JM, Kersun LS, et al. Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma. Pediatr Blood Cancer. 2005;44:232–239
  109. Voute PA, vander Kleij AJ, De Kraker J, et al. Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV. Eur J Cancer. 1995;31A:596–600
  110. Madsen MT, Bushnell DL, Juweid ME, et al. potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: A theoretic model. J Nucl Med. 2006;47:660–667
  111. Corbett R, Pinkerton R, Tait D, et al. I131metaiodobenzylguanidine and high-dose chemotherapy with bone marrow rescue in advanced neuroblastoma. J Nucl Biol Med. 1991;35:228–2331
  112. Klingebiel T, Bader P, Bares R, et al. Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high dose chemotherapy and immunotherapy: A pilot study. Eur J Cancer. 1998;34:1398–1402
  113. Yanik GA, Levine JE, Matthay KK, et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem cell support for the treatment of neuroblastoma. J Clin Oncol. 2002;20:2142–2149
  114. Matthay KK, Tan JC, Villablanca JG, et al. Phase 1 dose escalation of Iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: New approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol. 2006;24:500–506
  115. Garaventa A, Gambini C, Villavechia G, et al. Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine. Cancer. 2003;97:1332–1338
  116. Weiss B, Vora A, Huberty J, et al. Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma. J Pediatr Hematol Oncol. 2003;25:543–547
  117. De Kraker J, Hoefnagel CA, Caron H, et al. First line targeted radiotherapy (A new concept in the treatment of advanced stage neuroblastoma). Eur J Cancer. 1995;31A:600–602
  118. Hoefnagel CA, De Kraker J, Valdes Olmos RA, et al. 131I-MIBG as a first-line treatment in high-risk neuroblastoma patients. Nucl Med Commun. 1994;15:712–717
  119. Kushner BH, Kramer K, Cheung NKV. Phase II trial of the anti-GD2 monoclonal antibody 3F8 and granulocyte-macrophag colony-stimulating factor for neuroblastoma. J Clin Oncol. 2001;22:4189–4194
  120. Modak S, Cheung NKV. Antibody-based targeted radiation to pediatric tumors. J Nucl Med. 2005;46:157S–163S
  121. Koch CA, Pacak K, Chrousos GP. Endocrine tumors. In:  Pizzo PA,  Poplack DG editor. Principles and Practice of Pediatric Oncology. Philadelphia, PA: Lippincott Williams and Wilkins; 2006;p. 1139–1171
  122. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006;36:228–247
  123. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25:458–511
  124. Wick MR. Neuroendocrine neoplasia (Current concepts). Am J Clin Pathol. 2000;113:331–335
  125. Warren WH, Gould VE. Neuroendocrine tumors of the bronchopulmonary tract: A reappraisal of their classification after 20 years. Surg Clin North Am. 2002;82:525–540
  126. Parkes SE, Muir KR, al Sheyyab M, et al. Carcinoid tumours of the appendix in children 1957-1986: Incidence, treatment and outcome. Br J Surg. 1993;80:502–504
  127. Pappo AS, Furman WL. Management of infrequent cancers of childhood. In:  Pizzo PA,  Poplack DG editor. Principles and Practice of Pediatric Oncology. (ed 5). Philadelphia, PA: Lippincott Williams and Wilkins; 2006;p. 1172–1201
  128. Sperling MA. Hypoglycemia. In:  Behrman RE,  Kliegman RM,  Jenson HB editor. Nelson Textbook of Pediatrics. Philadelphia, PA: Saunders; 2004;p. 505–518
  129. Madeira I, Terris B, Voss M, et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut. 1998;43:422–427
  130. Hardy OT, Stanley CA. Hyperinsulism of infancy: Localization of focal forms. In:  Charron M editors. Practical Pediatric PET Imaging. New York: Springer; 2006;p. 479–484
  131. Marsh DJ, Learoyd DL, Robinson BG. Medullary thyroid carcinoma: Recent advances and management update. Thyroid. 1995;5:407–424
  132. Solcia E, Kloppel G, Sobin LH. Histological Typing of Endocrine Tumours. (ed 2). Heidelberg: World Health Organization; 2000;
  133. Ricke J, Klose KJ, Mignon M, et al. Standardisation of imaging in neuroendocrine tumours: Results of a European Delphi process. Eur J Radiol. 2001;37:8–17
  134. Kaltsas G, Korbonits M, Heintz E, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab. 2001;86:895–902
  135. Adams S, Baum R, Rink T, et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med. 1998;25:79–83
  136. Orlefors H, Sundin A, Garske U, et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocril Metab. 2005;90:3392–3400
  137. Pacak K, Linehan WM, Eisenhofer G, et al. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med. 2001;134:315–329
  138. Orlandi F, Caraci P, Mussa A, et al. Treatment of medullary thyroid carcinoma: An update. Endoc Rel Cancer. 2001;8:135–147
  139. Kaltsas GA, Papadogias D, Makras P, et al. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Rel Cancer. 2005;12:683–699
  140. Quigley AM, Buscombe JR, Shah T, et al. Intertumoural variability in functional imaging within patients suffering from neuroendocrine tumours (An observational, cross-sectional study). Neuroendocrinology. 2005;82:215–220

PII: S0001-2998(07)00030-X

doi: 10.1053/j.semnuclmed.2007.02.009

Seminars in Nuclear Medicine
Volume 37, Issue 4 , Pages 286-302 , July 2007

Article Tools

* Image Usage & Resolution